OreniPro

OreniPro is an investigational **once-daily oral prodrug of treprostinil** being developed by United Therapeutics for **idiopathic pulmonary fibrosis**. After administration, it is intended to convert in vivo to treprostinil, a **prostacyclin mimetic** that signals through prostacyclin pathway receptors to promote vasodilatory and antifibrotic biology associated with treprostinil exposure. The program is designed to improve convenience and tolerability relative to more frequent oral treprostinil dosing, and it has been described as a **development-stage small-molecule oral prodrug** that is **not approved for sale in any jurisdiction**.

Other names

oral treprostinil prodrug